Experimental HCV Drugs
Experimental HCV Drugs
BMS Withdraws FDA Application for Hepatitis C Drug Asunaprevir
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 08 October 2014 00:00
- Written by Bristol-Myers Squibb
Bristol-Myers Squibb unexpectedly announced this week that it will no longer seek U.S. Food and Drug Administration (FDA) approval for its experimental hepatitis C virus (HCV) protease inhibitor asunaprevir, despite promising results in clinical trials to date.
Sofosbuvir + Ribavirin To Be Studied in Children and Adolescents with Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 26 September 2014 00:00
- Written by HIVandHepatitis.com
A Phase 2 clinical trial is now underway to evaluate sofosbuvir (Sovaldi) plus ribavirin for children and adolescents, ages 3-17 years, with hepatitis C virus genotypes 2 or 3. Another study will follow to test the forthcoming sofosbuvir/ledipasir coformulation in pediatric patients.
Coverage of the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Details
- Category: HIV Treatment
- Published on Monday, 08 September 2014 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), September 5-9, in Washington, DC.
Conference highlights include experimental antiretroviral therapies for HIV, interferon-free treatment for hepatitis C, and news about other infectious diseases including tuberculosis, HPV, influenza, and Ebola virus.
Full listing of coverage by topic
9/8/14
ICAAC 2014: AbbVie 3D Hepatitis C Regimen Is Well-Tolerated in Phase 3 Trials
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 12 September 2014 00:00
- Written by Liz Highleyman
AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 SAPPHIRE trials, according to a pooled analysis presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC. While most patients experienced some adverse events, serious side effects were rare and few people discontinued treatment early for this reason.
ICAAC 2014: AbbVie 3D Regimen Shows High Cure Rates for Genotype 1b HCV Patients
- Details
- Category: Experimental HCV Drugs
- Published on Sunday, 07 September 2014 00:00
- Written by Liz Highleyman
AbbVie's interferon-free 3D regimen containing ABT-450, ombitasvir, and dasabuvir led to sustained virological response in nearly 100% of people with genotype 1b chronic hepatitis C regardless of unfavorable patient or viral characteristics, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC.
Web Design and Development by